F-star Therapeutics, Inc. (NASDAQ:FSTX – Get Rating) – Analysts at SVB Leerink issued their Q1 2023 EPS estimates for F-star Therapeutics in a research note issued on Wednesday, May 11th. SVB Leerink analyst D. Graybosch expects that the company will post earnings of ($0.53) per share for the quarter. SVB Leerink also issued estimates for F-star Therapeutics’ Q2 2023 earnings at ($0.53) EPS.
FSTX has been the subject of a number of other research reports. Zacks Investment Research upgraded F-star Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 8th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of F-star Therapeutics in a research report on Thursday, March 17th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $25.21.
A number of hedge funds and other institutional investors have recently made changes to their positions in FSTX. Cubist Systematic Strategies LLC acquired a new stake in F-star Therapeutics during the 4th quarter worth about $29,000. JPMorgan Chase & Co. acquired a new stake in F-star Therapeutics during the 4th quarter worth about $42,000. Envestnet Asset Management Inc. acquired a new stake in F-star Therapeutics during the 1st quarter worth about $48,000. Morgan Stanley boosted its position in F-star Therapeutics by 65.0% during the 2nd quarter. Morgan Stanley now owns 7,868 shares of the company’s stock worth $68,000 after acquiring an additional 3,100 shares during the period. Finally, Millennium Management LLC acquired a new stake in F-star Therapeutics during the 3rd quarter worth about $114,000. Hedge funds and other institutional investors own 51.67% of the company’s stock.
F-star Therapeutics Company Profile (Get Rating)
F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.
- Get a free copy of the StockNews.com research report on F-star Therapeutics (FSTX)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.